Compare DexCom, Inc. (DXCM) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Sunrun Inc — how do they compare? DexCom, Inc. trades at $84.46 (market cap $31.81B), while Sunrun Inc trades at $7.65 (market cap $1.83B). The key difference: DexCom, Inc. is far larger — about 17.4× Sunrun Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Sunrun Inc for 16 Days on average.
| DXCM | RUN | |
|---|---|---|
Market Cap | $31.81B | $1.83B |
Volume | 2,861,821 | 13,379,830 |
Sector | Health | Energy |
52-Week High | $92.34 | $21.41 |
52-Week Low | $54.84 | $7.59 |
Typical Hold Time | 62 Days | 16 Days |
Enterprise Value | $31.26B | $16.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Sunrun (RUN) trades at $7.61, down 2.06% amid broader solar sector weakness. The stock shows bearish technical signals with oversold RSI levels, while fundamentals reveal strong earnings beats but negative operating cash flow. Recent partnerships with Tesla and Voltus highlight growth potential in distributed energy, though high borrowing costs pressure project financing.
Wall Street maintains a bullish consensus with a $16.56 price target (62% buy ratings), but risks include persistent cash burn, interest expense burden, and solar industry headwinds. The stock trades at discounted valuations (P/E 5.18, P/B 0.53) but requires improved profitability to justify analyst optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
